| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
70,650,000 |
| Market
Cap: |
3.95(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$38.62 - $89.12 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile CRISPR Therapeutics is a gene editing company focused on the development of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) based therapeutics. CRISPR/Cas9 is a technology for gene editing, the process of altering specific sequences of genomic DNA. Co. is developing several gene-edited allogeneic cell therapy programs. Co.'s main product candidate, CTX001, is an investigational ex vivo CRISPR gene-edited therapy that is being evaluated for patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce fetal hemoglobin in red blood cells.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
22,948 |
163,087 |
163,087 |
413,087 |
| Total Sell Value |
$1,362,031 |
$11,023,312 |
$11,023,312 |
$25,502,855 |
| Total People Sold |
2 |
4 |
4 |
4 |
| Total Sell Transactions |
2 |
13 |
13 |
23 |
| End Date |
2024-03-28 |
2023-12-26 |
2023-06-27 |
2022-06-27 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Dylan-Hyde Tyler |
Chief Legal Officer |
• – – |
2017-04-19 |
4 |
AS |
$17.49 |
$129,165 |
D/D |
(7,240) |
197,964 |
|
- |
|
| Emster Kurt Von |
Director |
– • – |
2016-10-24 |
4 |
B |
$14.00 |
$784,000 |
I/I |
56,000 |
2,601,814 |
2.1 |
- |
|
| Emster Kurt Von |
Director |
– • – |
2016-10-24 |
4 |
A |
$0.00 |
$0 |
I/I |
2,545,814 |
2,545,814 |
|
- |
|
| Lundberg Sven Ante |
Chief Scientific Officer |
• – – |
2016-10-24 |
4 |
B |
$14.00 |
$5,600 |
I/I |
400 |
505,617 |
1.99 |
- |
|
| Lundberg Sven Ante |
Chief Scientific Officer |
• – – |
2016-10-24 |
4 |
A |
$0.00 |
$0 |
D/D |
55,217 |
505,217 |
|
- |
|
| Versant Venture Capital V (canada), Lp |
10% Owner |
– – • |
2016-10-24 |
4/A |
A |
$0.00 |
$0 |
I/I |
6,508,699 |
79,478 |
|
- |
|
| Versant Venture Capital V (canada), Lp |
10% Owner |
– – • |
2016-10-24 |
4/A |
B |
$14.00 |
$2,254,000 |
I/I |
161,000 |
185,987 |
1.5 |
- |
|
| Woiwode Thomas |
Director |
– • – |
2016-10-24 |
4 |
A |
$0.00 |
$0 |
I/I |
6,508,699 |
79,478 |
|
- |
|
| Woiwode Thomas |
Director |
– • – |
2016-10-24 |
4 |
B |
$14.00 |
$2,254,000 |
I/I |
161,000 |
185,987 |
2.1 |
- |
|
| Bolzon Bradley J Phd |
Director |
– • – |
2016-10-24 |
4 |
A |
$0.00 |
$0 |
I/I |
6,508,699 |
79,478 |
|
- |
|
| Bolzon Bradley J Phd |
Director |
– • – |
2016-10-24 |
4 |
B |
$14.00 |
$2,254,000 |
I/I |
161,000 |
185,987 |
2.1 |
- |
|
| Celgene Corp /de/ |
10% Owner |
– – • |
2016-10-24 |
4/A |
B |
$14.00 |
$11,202,100 |
I/I |
800,150 |
4,834,980 |
1.5 |
- |
|
| Celgene Corp /de/ |
10% Owner |
– – • |
2016-10-24 |
4/A |
A |
$0.00 |
$0 |
I/I |
4,034,830 |
4,034,830 |
|
- |
|
| Versant Venture Capital V (canada), Lp |
10% Owner |
– – • |
2016-10-24 |
4 |
A |
$14.00 |
$2,254,000 |
I/I |
161,000 |
185,987 |
|
- |
|
| Coles N Anthony |
Director |
– • – |
2016-10-24 |
4 |
A |
$14.00 |
$980,000 |
I/I |
70,000 |
70,000 |
|
- |
|
| Glaxosmithkline Plc |
10% Owner |
– – • |
2016-10-24 |
4 |
B |
$14.00 |
$931,000 |
I/I |
66,500 |
3,220,627 |
1.5 |
- |
|
| Glaxosmithkline Plc |
10% Owner |
– – • |
2016-10-24 |
4 |
A |
$0.00 |
$0 |
I/I |
3,154,127 |
3,154,127 |
|
- |
|
| George Simeon |
Director |
– • – |
2016-10-24 |
4 |
B |
$14.00 |
$931,000 |
I/I |
66,500 |
3,220,627 |
2.1 |
- |
|
| George Simeon |
Director |
– • – |
2016-10-24 |
4 |
A |
$0.00 |
$0 |
I/I |
3,154,127 |
3,154,127 |
|
- |
|
| Celgene Corp /de/ |
10% Owner |
– – • |
2016-10-24 |
4 |
B |
$14.00 |
$11,202,100 |
D/D |
800,150 |
4,834,980 |
2.45 |
- |
|
| Celgene Corp /de/ |
10% Owner |
– – • |
2016-10-24 |
4 |
A |
$0.00 |
$0 |
D/D |
4,034,830 |
4,034,830 |
|
- |
|
| Hadley Harbor Master Investors (cayman) L.p. |
10% Owner |
– – • |
2016-10-24 |
4 |
A |
$0.00 |
$0 |
D/D |
744,380 |
744,380 |
|
- |
|
| Bolzon Bradley J Phd |
Director |
– • – |
2016-10-18 |
3/A |
IO |
$0.00 |
$0 |
I/I |
0 |
923,662 |
|
- |
|
| Woiwode Thomas |
Director |
– • – |
2016-10-18 |
3/A |
IO |
$0.00 |
$0 |
I/I |
0 |
923,662 |
|
- |
|
| Bayer Aktiengesellschaft |
10% Owner |
– – • |
2016-10-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,105,330 |
|
- |
|
485 Records found
|
|
Page 19 of 20 |
|
|
1.99 (3.43%) 
